Invention Grant
- Patent Title: Human neuregulin-1 (NRG-1) recombinant fusion protein compositions and methods of use thereof
-
Application No.: US17327494Application Date: 2021-05-21
-
Publication No.: US11718652B2Publication Date: 2023-08-08
- Inventor: John Li , Shengwei Li , Dixiang Luo , Yiran Wu , Ming Zhou , Yang Wang , Xiaolei Zhuang , Liang Hua , Pengyi Luo
- Applicant: Salubris Biotherapeutics, Inc. , Salubris (Chengdu) Biotech Co., Ltd.
- Applicant Address: US MD Gaithersburg
- Assignee: Salubris Biotherapeutics, Inc.
- Current Assignee: Salubris Biotherapeutics, Inc.
- Current Assignee Address: US MD Gaithersburg;
- Agency: Cooley LLP
- Agent Matthew Pavao; Jessica D. Cande
- Main IPC: C07K14/475
- IPC: C07K14/475 ; C12N15/90 ; A61K38/00
Abstract:
The present invention relates to a recombinant fusion protein comprising a fragment of the cardioprotective protein neuregulin-1 (NRG-1) fused to a monoclonal antibody (mAb) backbone and to a method of treating a disease or condition in a subject in need thereof comprising administering a therapeutically effective amount of the recombinant fusion protein or the pharmaceutical composition comprising the recombinant fusion protein disclosed herein.
Public/Granted literature
- US20210347841A1 HUMAN NEUREGULIN-1 (NRG-1) RECOMBINANT FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF Public/Granted day:2021-11-11
Information query
